Lilly CEO Lechleiter joins the busy buyside in biotech

Lilly CEO John Lechleiter

Eli Lilly ($LLY) CEO John Lechleiter counts himself as a buyer in a busy M&A market. Lechleiter recently pointed to animal health as well as key therapeutic areas like neurosciences, diabetes and cancer, according to a report from Reuters. And he's likely to have plenty of competition on the bidder side of the M&A game this year. Roger Perlmutter at Merck ($MRK) pointed to early-stage therapies as a likely target while Teva's ($TEVA) new CEO wasted no time in pinning down his first buyout. "I think deal making this year will be even better because there was a lot of validation last year," Joseph Gulfo, chief executive officer at Breakthrough Medical Innovations, tells Reuters. "The new discoveries and data have sparked a tremendous amount of interest from the bigger companies." Of course, every year starts out with some boom projections at the annual J.P. Morgan conference in San Francisco. Story

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.